Details

Konvencija o prihodnosti Evrope in Slovenija : diplomsko delo
ID Vonarb, Jean-Pierre (Author), ID Brezovšek, Marjan (Mentor) More about this mentor... This link opens in a new window

URLURL - Presentation file, Visit http://dk.fdv.uni-lj.si/dela/Vonarb-Jean-Pierre.PDF This link opens in a new window

Language:Slovenian
Keywords:Evropska unija, Slovenija
Work type:Undergraduate thesis
Typology:2.11 - Undergraduate Thesis
Organization:FDV - Faculty of Social Sciences
Place of publishing:Ljubljana
Publisher:[J.-P.Vonarb]
Year:2003
Number of pages:78 f.
PID:20.500.12556/RUL-6252 This link opens in a new window
UDC:341.24(043.2)
COBISS.SI-ID:22386781 This link opens in a new window
Publication date in RUL:11.07.2014
Views:2100
Downloads:164
Metadata:XML DC-XML DC-RDF
:
VONARB, Jean-Pierre, 2003, Konvencija o prihodnosti Evrope in Slovenija : diplomsko delo [online]. Bachelor’s thesis. Ljubljana : J.-P.Vonarb. [Accessed 25 March 2025]. Retrieved from: http://dk.fdv.uni-lj.si/dela/Vonarb-Jean-Pierre.PDF
Copy citation
Share:Bookmark and Share

Secondary language

Language:Unknown
Keywords:European union, Slovenia

Similar documents

Similar works from RUL:
  1. ǂThe ǂimportance of cancer stem cells and epithelial-mesenchymal transition in the progression of non-small cell lung cancer
  2. Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
  3. Study of phosphatidylethanolamine N-methyltransferase gene expression in non-small cell lung cancer tissue
  4. Usefulness of immunohistochemically determined epidermal growth factor receptor mutations in lung cancer
  5. Diabetes mellitus and physical activity
Similar works from other Slovenian collections:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Back